Evidence map›Paper›PMID 33173913›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model.

Prashant Dogra, Javier Ruiz-Ramírez, Kavya Sinha, Joseph D Butner, Maria J Peláez, Manmeet Rawat, Venkata K Yellepeddi, Renata Pasqualini, Wadih Arap, H Dirk Sostman and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Prashant DograMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Javier Ruiz-RamírezMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Kavya SinhaDeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
Joseph D ButnerMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Maria J PeláezMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Manmeet RawatDepartment of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
Venkata K YellepeddiDivision of Clinical Pharmacology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, UT 84132, USA.
Renata PasqualiniRutgers Cancer Institute of New Jersey, Newark, NJ, 07101, USA.
Wadih ArapRutgers Cancer Institute of New Jersey, Newark, NJ, 07101, USA.
H Dirk SostmanWeill Cornell Medicine, New York, NY 10065, USA.
Vittorio CristiniMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Zhihui WangMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
Houston Methodist · USRutgers, The State University of New Jersey · USUniversity of New Mexico · USUniversity of Utah · US

Funding

Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$9.3M
Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the PancreasU01CA196403 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2015 to 2020
$5.8M
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate CancerR01CA226537 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ARAP, WADIH, BRINKER, C JEFFREY · 2018 to 2022
$3.2M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modelingU01CA213759 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOPEZ-BERESTEIN, GABRIEL · 2017 to 2021
$2.5M
NCI NIH HHS R01 CA222007NCI NIH HHS R01 CA226537NCI NIH HHS U01 CA196403NCI NIH HHS U01 CA213759NCI NIH HHS U54 CA210181
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pathogen of immense public health concern. Efforts to control the disease have only proven mildly successful, and the disease will likely continue to cause excessive fatalities until effective preventative measures (such as a vaccine) are developed. To develop disease management strategies, a better understanding of SARS-CoV-2 pathogenesis and population susceptibility to infection are needed. To this end, physiologically-relevant mathematical modeling can provide a robust

Indexed as

COVID-19in silico clinical trialsmathematical modelingpharmacokineticsSARS-CoV-2viral dynamics

Identifiers

PMID33173913
PMCPMC7654909
OpenAlexW3095337613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.